false
OasisLMS
Login
Catalog
Kidney Week 2026 Early Program On-Demand - Advance ...
Gene Editing for PKD
Gene Editing for PKD
Back to course
[Please upgrade your browser to play this video content]
Video Transcription
Video Summary
Dr. Zhaogang Li discussed gene-editing approaches for autosomal dominant polycystic kidney disease (ADPKD), focusing on in vivo CRISPR base editing. His team tested an editor designed to correct a disease-associated point mutation in PKD1-RC mice. A single injection delayed kidney cyst growth, reduced heart enlargement, restored polycystin-1 expression, and extended lifespan. Benefits persisted for up to six months. A kidney-specific promoter improved editing efficiency to roughly 20–22%, compared with about 10% using a broadly active promoter, while reducing editing in the heart. Initial safety assessments indicated tolerable toxicity and low unintended editing.<br /><br />The work remains preclinical, and the speaker emphasized that editing efficiency must improve substantially—potentially above 50%—for effective treatment of human disease. Ongoing efforts include kidney-targeted delivery systems, such as lipid nanoparticles, and prime editing, which could address mutations that base editing cannot. Li expressed optimism that continued advances in delivery, efficiency, and safety could eventually make gene editing a viable treatment for ADPKD and other genetic kidney diseases.
Asset Caption
Xiaogang Li, PhD
Meta Tag
Speaker
Xiaogang Li
Keywords
autosomal dominant polycystic kidney disease
CRISPR base editing
PKD1 mutation
kidney-specific promoter
in vivo gene editing
lipid nanoparticles
prime editing
Xiaogang Li
×
Please select your language
1
English